Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.
The study included healthy adult men, aged 25-45, who ingested one of three butyrate forms, with blood samples and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback